Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 07-22-2003, 04:28 AM   #1
Paul C.
Posts: n/a
During a presentation in Taipei on Monday the CEO of US therapeutics company Receptor BioLogix Dr. Michael Shepard outlined his company's anti-cancer drug development pipeline.

Shepard's talk focused on the company's new drug Herstatin designed to act on tumor cells that overexpress HERS-2—human epidermal growth factor receptor 2.

At this early stage of drug testing Herstatin is showing effectiveness on a wider range of cancers than the earlier-generation anti-cancer HERS-2 drug Herceptin co-discovered by Shepard and now produced by US-based Genentech mainly for breast cancer treatment.
  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 05:49 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter